An Open-Label Study of Azetukalner in Major Depressive Disorder

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).

NCT Number	NCT06922110
Lead Sponsor	Xenon Pharmaceuticals Inc.
Conditions	Major Depressive Disorder
Enrollment	460 participants
Start Date	2025-03-18
Primary Completion	2027-01 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-03